NZSE:GXH

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Green Cross Health Limited provides health support, care, and advice services to communities in New Zealand. More Details


Snowflake Analysis

Undervalued with mediocre balance sheet.

Share Price & News

How has Green Cross Health's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GXH has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

3.0%

GXH

-1.0%

NZ Consumer Retailing

-1.1%

NZ Market


1 Year Return

-5.5%

GXH

0.5%

NZ Consumer Retailing

1.6%

NZ Market

Return vs Industry: GXH underperformed the NZ Consumer Retailing industry which returned 0.5% over the past year.

Return vs Market: GXH underperformed the NZ Market which returned 1.6% over the past year.


Shareholder returns

GXHIndustryMarket
7 Day3.0%-1.0%-1.1%
30 Day3.0%-8.3%-1.2%
90 Day2.0%-0.01%4.0%
1 Year-2.2%-5.5%4.7%0.5%6.1%1.6%
3 Year-43.7%-51.9%36.4%27.3%42.6%22.9%
5 Year-41.6%-53.2%51.9%34.8%95.7%46.5%

Price Volatility Vs. Market

How volatile is Green Cross Health's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Green Cross Health undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: GXH (NZ$1.04) is trading below our estimate of fair value (NZ$12.21)

Significantly Below Fair Value: GXH is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: GXH is good value based on its PE Ratio (11x) compared to the XX Consumer Retailing industry average (20.9x).

PE vs Market: GXH is good value based on its PE Ratio (11x) compared to the NZ market (22.1x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GXH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GXH is good value based on its PB Ratio (1.2x) compared to the XO Consumer Retailing industry average (2.1x).


Next Steps

Future Growth

How is Green Cross Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

10.6%

Forecasted Consumer Retailing industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Green Cross Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Green Cross Health performed over the past 5 years?

-2.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GXH has high quality earnings.

Growing Profit Margin: GXH's current net profit margins (2.4%) are lower than last year (2.8%).


Past Earnings Growth Analysis

Earnings Trend: GXH's earnings have declined by 2.8% per year over the past 5 years.

Accelerating Growth: GXH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: GXH had negative earnings growth (-16.2%) over the past year, making it difficult to compare to the Consumer Retailing industry average (9.6%).


Return on Equity

High ROE: GXH's Return on Equity (12.6%) is considered low.


Next Steps

Financial Health

How is Green Cross Health's financial position?


Financial Position Analysis

Short Term Liabilities: GXH's short term assets (NZ$111.7M) exceed its short term liabilities (NZ$108.9M).

Long Term Liabilities: GXH's short term assets (NZ$111.7M) do not cover its long term liabilities (NZ$133.0M).


Debt to Equity History and Analysis

Debt Level: GXH's debt to equity ratio (41.9%) is considered high.

Reducing Debt: GXH's debt to equity ratio has increased from 39.8% to 41.9% over the past 5 years.

Debt Coverage: GXH's debt is well covered by operating cash flow (96.2%).

Interest Coverage: GXH's interest payments on its debt are well covered by EBIT (4.7x coverage).


Balance Sheet


Next Steps

Dividend

What is Green Cross Health current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GXH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GXH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GXH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GXH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: GXH is not paying a notable dividend for the NZ market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GXH's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Rachael Newfield

1.67yrs

Tenure

Ms. Rachael Newfield has been the Group Chief Executive Officer of Green Cross Health Limited since January 2019.


Leadership Team

NamePositionTenureCompensationOwnership
Rachael Newfield
Group Chief Executive Officer1.67yrsno datano data
Ben Doshi
Group CFO & Company Secretary0.92yrno datano data
Mark Smith
Chief Information Officer2.5yrsno datano data
Grant Bai
Chief Executive Officer of Pharmacy & Medical6.92yrsno data0.50%
NZ$ 739.2k
Alison Van Wyk
Chief Executive Officer of Community Health Divisionno datano datano data

2.1yrs

Average Tenure

Experienced Management: GXH's management team is considered experienced (2.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kimmitt Ellis
Independent Chairman0.75yrNZ$40.00kno data
Peter Merton
Non-Executive Director11yrsNZ$77.92kno data
John Bolland
Non-Executive Director11.08yrsNZ$35.00kno data
John Bagnall
Non-Executive Director11.08yrsNZ$35.00k32.09%
NZ$ 47.8m
Kenneth Orr
Independent Director8.5yrsNZ$70.00kno data
Peter Williams
Non-Executive Director3.33yrsNZ$35.00kno data
Carolyn Steele
Independent Director3.25yrsNZ$70.00k0.035%
NZ$ 52.0k

8.5yrs

Average Tenure

Experienced Board: GXH's board of directors are considered experienced (8.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Green Cross Health Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Green Cross Health Limited
  • Ticker: GXH
  • Exchange: NZSE
  • Founded: 1999
  • Industry: Drug Retail
  • Sector: Consumer Retailing
  • Market Cap: NZ$148.879m
  • Shares outstanding: 143.15m
  • Website: https://www.greencrosshealth.co.nz

Number of Employees


Location

  • Green Cross Health Limited
  • Building B
  • Ground Floor
  • Auckland
  • 1051
  • New Zealand

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GXHNZSE (New Zealand Stock Exchange)YesOrdinary SharesNZNZDOct 2009
PRCX.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDOct 2009

Biography

Green Cross Health Limited provides health support, care, and advice services to communities in New Zealand. It operates in three segments: Pharmacy Services, Medical Services, and Community Health. The Ph ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/20 19:07
End of Day Share Price2020/09/18 00:00
Earnings2020/03/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.